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The diagnosis of dementia of the Alzheimer type (DAT) depends on the clinician's 
ability to document intellectual impainnent in the patient and to exclude other causes 
of dementia. About 50% of all demented patients entering a hospital are ultimately 
found at postmortem examination to have Alzheimer's disease. However, using the 
most rigorous criteria the accuracy of correct clinical diagnosis at autopsy approaches 
only 80-90% and this excludes some unusual patients. Most investigators use the 
Diagnostic and Statistical Manual of Mental Disorder-third ed. (DSM-III) criteria for 
dementia, a rating of perfonnance in activities of daily living, and an assessment of 
personality and intellectual function for diagnosis. Two clinical rating scales: the 
Blessed Dementia Rating Scale (parts 1 and 2) and the Clinical Dementia Rating 
Scale, are used frequently and seem to identify patients with DAT with greater 
accuracy than other scales. 
Our assessment protocol for dementia includes a quantitative neurological exam-
ination because certain motor manifestations have been observed in DAT: myoclonus, 
rigidity, stooped posture, and bradykinesia. We found these clinical features to be 
useful in predicting the course in some patients. Our data indicate clinical hetero-
geneity in DAT and may suggest the presence of unique subgroups. 
METHODS 
We reviewed the records of 138 patients who met our research criteria for DAT. 
These included: history of intellectual impainnent for at least 6 months, objective 
neuropsychological evidence of dementia, and DMS-m criteria for primary degener-
ative dementia. We accepted only those patients whose laboratory studies were com-
patible with a diagnosis of DAT. We excluded patients with a history of affective 
disorder, Parkinson's disease, stroke, cancer, anoxia, or seizures. 
Every patient was interviewed with a family member present to verify all historical 
information. The neurological examination included a modified version of the Co-
lumbia University Parkinson's Disease rating scale and dyskinesia rating scale. Activ-
ities of daily life were assessed by the Blessed Dementia Rating Scale (BORS) 
(part 1). A brief neuropsychological test, a modified version of the Mini-Mental State 
Examination (mMMS), and a semistructured interview to derive symptoms for depres-
sion and psychosis were completed. 
A subset of the original cohort was identified and included in a longitudinal anal-
ysis. This group consisted of 62 individuals who received primary treatment at our 
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medical center; each had been evaluated on at least two occasions separated by a 
minimum of 6 months. 
A database from the original 138 patients was used to isolate clinical factors, such 
as family history, age-at-onset, or motor manifestations, that were related to mMMS 
performance and BORS. We then examined the utility of these factors in predicting 
the decline in intellectual skills and functional capacity in the 62 patients from the 
longitudinal study. 
RESULTS 
The mean age of the large patient group was 68. 9 ( ± 9. 7). Modified MMS and 
BORS scores varied widely but correlated (r = -0.54, P < 0.001). BORS increased 
and mMMS decreased significantly with duration of symptoms (r = -0.2, 
P < 0.01). Neither age at the first examination or age-at-onset of dementia correlate--J 
with mMMS or BORS. . 
In the 138 patients, 25.9% (36) had extrapyramidal signs consisting of rigidity,. 
bradykinesia, and stooped posture unrelated to medication. BORS and mMMS were 
significantly worse in this group compared to the others, but there was no difference 
in age, age-at-onset or duration of symptoms. Twelve (11.5%) had myoclonus and 
were younger at the onset of their dementia. Myoclonus and extrapyramidal signs 
coexisted in five patients. BORS was significantly higher and mMMS lower in the 
group with myoclonus compared to all patients in other groups. Another 12 patients 
had extrapyramidal signs which we considered drug induced; mMMS and BORS 
scores were significantly worse in these patients compared to all groups except those 
with myoclonus. 
The 62 patients in the longitudinal component of this study were slightly younger 
at their initial examination (66.7 ± 9.3) and had lower BORS scores. Each patient 
had been examined at least twice over a 6-month interval. The majority had been 
examined a number of times over a period of 4 years. 
The 62 patients were separated into four groups: typical DAT (n = 16 only 
dementia), DAT with extrapyramidal signs (n = 30; sporadic = 14 and drug-
induced = 16), DAT with myoclonus (n = 9), and DAT-benign (n = 7 slow 
progression). Myoclonus and extrapyramidal signs coexisted in three patients. 
Two groups, those with extrapyramidal signs and those with myoclonus initially, 
had significantly higher BORS scores and lower mMMS scores at the last examination 
(P < 0. 01 for both measures) than the typical or benign patient groups. -They also 
experienced a more rapid change in these measures over time than the other groups. 
Patients with drug-induced extrapyramidal signs deteriorated even more rapidly than 
the other groups. The seven benign patients, by contrast, progressed very little over 
the study period in comparison to the typical patient group. 
Family history of dementia or age-at-onset were not distinguishing features. How-
ever, we found that patients with evidence of thought disorder, defined by the presence 
of persistent delusions or hallucinations, also deteriorated more rapidly than those 
without these manifestations (BORS, P < 0.05 and mMMS, P < 0.01). Thought 
disorder ocurred most frequently in patients with extrapyramidal signs and myoclonus, 
but it was also present in a few typical patients and precipitated a rapid decline in a 
single benign patient. 
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COMMENT 
The demonstration of heterogeneity in our patients has both practical and theoretical 
importance. The presence of myoclonus or extrapyramid8I signs at the initial exam-
ination was strongly predictive of a more rapid progression of illness, imparting a poor 
prognosis for these patients since the motor manifestations do not resolve. More 
importantly these observations may indicate biological heterogeneity. The presence of 
myoclonus in patients with Alzheimer's disease has been found to be the best predictor 
of low choline acetyltransferase activity in postmortem brain. Patients with autopsy 
confirmed Alzheimer's disease may also have degeneration in substantia nigra and 
Lewy bodies suggesting a possible overlap with Parkinson's disease (PD), and loss of 
cells in the basal forebrain can occur in both DAT and PD. However, the biochemical 
changes of Alzheimer's disease can be observed in demented parkinsonians, but the 
converse is not always found. 
The benign group is unusual because of the slow progression, but this may also 
identify a biological subgroup. "Simple dementia" is a term used to describe a milder 
form of the disease that is characterized by less striking cell loss, neuritic plaques, and 
tangles. The biochemical changes are also less pronounced. Postmortem confirmation 
of diagnoses in this group will be essential to determine its relationship to Alzheimer's 
disease. 
Psychosis was also associated with a poor prognosis, and could also define a 
subgroup. However, psychosis occurred in a few patients in every subgroup we 
defined suggesting that it is a malignant but nonspecific manifestation of DAT. Longi-
tudinal study of this phenomenon will determine if it represents a unique subgroup. 
Our data suggest the existence of four unique subgroups of DAT: extrapyramidal, 
myoclonic, typical, and benign. Although there is some overlap in these groups their 
course and prognosis are distinctly different. Four of our 62 patients have died and 
Alzheimer's disease was confirmed in all, but we expect our diagnostic accuracy to 
remain around 90%. 
DAT may be a heterogeneous disorder even when restrictive criteria are used for 
research diagnosis. Certain motor manifestations and psychiatric features have re-
markable prognostic implications. The pathological and biochemical issues raised by 
these observations need careful consideration in longitudinal studies of DAT. 
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